Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer

09/17/2019 | 01:17am EDT

- Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 -

BOTHELL, Wash. and TOKYO, September 16, 2019 - Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the investigational agent enfortumab vedotin and granted Priority Review for the treatment of patients with locally advanced or metastatic urothelial cancer who have received a PD-1/L1 inhibitor and who have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. The filing is based on results from the first cohort of patients in the EV-201 pivotal phase 2 clinical trial that were presented as a late-breaking oral presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in June 2019. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of March 15, 2020. Enfortumab vedotin is a novel investigational antibody-drug conjugate (ADC) that targets Nectin-4, a protein that is highly expressed in urothelial cancers.1

The FDA granted enfortumab vedotin Breakthrough Therapy designation in March 2018, for patients with locally advanced or metastatic urothelial cancer whose disease has progressed during or following checkpoint inhibitor therapy.

'The FDA's filing of the application for enfortumab vedotin and granting of Priority Review is a significant milestone toward offering a new treatment to patients with advanced urothelial cancer who have a clear unmet need,' said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics.

'If approved, enfortumab vedotin will likely play an important role in the treatment of advanced urothelial cancer, and we look forward to working with the FDA as the review process advances,' said Andrew Krivoshik, M.D., Ph.D., Senior Vice President and Oncology Therapeutic Area Head at Astellas.

Click below for a copy of the full press release

Disclaimer

Astellas Pharma Inc. published this content on 17 September 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 September 2019 05:16:03 UTC


ę Publicnow 2019
All news about ASTELLAS PHARMA INC.
08:05aASTELLAS PHARMA INC. : will present 12-week results (S-13) from the pivotal Phase 3 SKYLIG..
AQ
09/22Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic..
AQ
09/22Astellas to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2Ö Trial in Ora..
CI
09/22ASTELLAS PHARMA : to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2™ ..
PU
09/21ASTELLAS PHARMA : Science-based Exercise at Home with Fit-eNce HomeTM Pilot Sales Begins T..
PU
09/20ASTELLAS PHARMA : ' and Pfizer's XTANDI« (enzalutamide) Reduced Risk of Death by 34% in Me..
PU
09/20ASTELLAS PHARMA : ' and pfizer's xtandi (enzalutamide) reduced risk of death by 34% in men..
AQ
09/09ASTELLAS PHARMA : Updates “Contact for Potential Acquisition of ' R&D Programs&rdquo..
PU
09/02ASTELLAS PHARMA : Nitto, and M. Heart Partnering for ECG testing service
PU
09/01Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked My..
CI
More news
Financials
Sales 2022 1 325 B 12 037 M 12 037 M
Net income 2022 194 B 1 767 M 1 767 M
Net cash 2022 478 B 4 339 M 4 339 M
P/E ratio 2022 17,6x
Yield 2022 2,68%
Capitalization 3 453 B 31 513 M 31 372 M
EV / Sales 2022 2,25x
EV / Sales 2023 1,89x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 863,50 JPY
Average target price 2 451,54 JPY
Spread / Average Target 31,6%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.16.91%31 513
JOHNSON & JOHNSON4.16%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.32%246 414
NOVO NORDISK A/S50.62%232 291
ELI LILLY AND COMPANY35.22%206 972